Biocatalysts and methods for the synthesis of substituted lactams
US-9624478-B2 · Apr 18, 2017 · US
US10858635B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10858635-B2 |
| Application number | US-202016825641-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 20, 2020 |
| Priority date | Sep 8, 2011 |
| Publication date | Dec 8, 2020 |
| Grant date | Dec 8, 2020 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present disclosure relates to transaminase polypeptides capable of aminating a dicarbonyl substrate, and polynucleotides, vectors, host cells, and methods of making and using the transaminase polypeptides.
Opening claim text (preview).
What is claimed is: 1. An engineered transaminase polypeptide comprising an amino acid sequence having at least 80% sequence identity to reference sequence SEQ ID NO:4 and at least an amino acid residue difference as compared to SEQ ID NO:4 at residue position X323. 2. The engineered polypeptide of claim 1 , in which X323 is C. 3. The engineered polypeptide of claim 2 , wherein the amino acid sequence further comprises one or more residue differences as compared to SEQ ID NO:4 selected from: X42G; X54P; X54R; X69A; X69G; X69T; X122M; X124F; X124L; X124N; X124R; X126A; X126T; X150S; X152C; X152G; X1521; X152L; X1525; X156A; X1565; X156T; X157L; X165N, X192A, X193G, X192H, X192K, X192N, X193Q, X192R, and X1925. 4. The engineered polypeptide of claim 2 , wherein the amino acid sequence further comprises a combination of residue differences selected from: (a) X124W and X327L; (b) X209M and X300G; (c) X122F, X223V and X284A; (d) X192A, X215H and X311T; (e) X62N, X124F, X126A and X136L; (f) X124W, X126A, X136L, X192A and X284A; and (g) X124W, X126A, X136L, X152R/X152L/X1521, and X192A. 5. The engineered polypeptide of claim 1 , in which the amino acid sequence further comprises a residue difference as compared to SEQ ID NO:4 of X284A. 6. An engineered polynucleotide encoding the polypeptide of claim 1 . 7. A vector comprising the polynucleotide of claim 6 . 8. A host cell comprising the vector of claim 7 . 9. A method of converting compound 2 to compound 1, comprising contacting compound 2 with the engineered polypeptide of claim 1 , under suitable reaction conditions to produce compound 1. 10. A method of converting compound 2 to compound 1d and compound 1a comprising contacting compound 2 with the engineered polypeptide of claim 1 , under suitable reaction conditions to produce compound 1d and 1a, under suitable reaction conditions wherein said engineered polypeptide comprises at least 1.5 fold the activity of SEQ ID NO:4.
Transaminases (2.6.1) · CPC title
transferring nitrogenous groups (2.6) · CPC title
Amino acids other than alpha- or beta amino acids, e.g. gamma amino acids · CPC title
containing a six-membered hetero ring · CPC title
Amines; Imines · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.